Table 1.
Clinicopathological Characteristics of 54 NSCLC Patients.
| Characteristics | Patients n = 54, No. (%) | FR +CTC≤7.9 FU/3 ml n = 14, No. (%) | FR +CTC>7.9 FU/3 ml n = 40, No. (%) | P value |
|---|---|---|---|---|
| Age (years-old, mean ± SD) | 60.6 ± 10.2 | 60.4 ± 11.2 | 60.7 ± 10.0 | >0.999 |
| <60 | 21 (38.9%) | 5 (35.7%) | 16 (40.0%) | |
| ≥60 | 33 (61.1%) | 9 (64.3%) | 24 (60.0%) | |
| Sex | 0.7725 | |||
| Male | 30 (55.6%) | 8 (57.1%) | 22 (55.0%) | |
| Female | 24 (44.4%) | 6 (42.9%) | 18 (45.0%) | |
| Tumor size (cm, mean ± SD) | 3.1 ± 2.0 | 0.7812 | ||
| <3 cm | 27 (50%) | 9 (64.3%) | 18 (45.0%) | |
| ≥3 cm | 27 (50%) | 5 (35.7%) | 22 (55.0%) | |
| Pathological type | NA | |||
| AIS/MIA | 5 (9.3%) | 1 (7.1%) | 4 (10%) | |
| invasive adenocarcinoma | 33 (61.1%) | 9 (64.3%) | 24 (60.0%) | |
| squamous cell carcinoma | 11 (20.4%) | 2 (14.3%) | 9 (22.5%) | |
| large cell carcinoma | 3 (5.5%) | 2 (14.3%) | 1 (2.5%) | |
| adenosquamous carcinoma | 2 (3.7%) | 0 | 2 (5%) | |
| Tumor differentiationa | 0.4330 | |||
| High | 7 (14.6%) | 3 (25.0%) | 4 (11.1%) | |
| Middle/Middle-Low | 26 (54.2%) | 5 (41.7%) | 21 (58.3%) | |
| Low | 15 (31.2%) | 4 (33.3%) | 11 (30.6%) | |
| Adenocarcinoma subtypa | 0.2374 | |||
| Leptic/Acinar | 18 (%) | 7 (77.8%) | 11 (50.0%) | |
| Mucinous/micropapillary/Solid | 13 (%) | 2 (22.2%) | 11 (50.0%) | |
| T stagea | >0.9999 | |||
| Tis+T1 | 26 (55.3%) | 7 (58.3%) | 19 (54.3%) | |
| T2+T3 | 21 (44.7%) | 5 (41.7%) | 16 (45.7%) | |
| N stagea | 0.7337 | |||
| N0 | 31 (59.6%) | 7 (58.3%) | 14 (46.7%) | |
| N1-2 | 21 (40.4%) | 5 (41.7%) | 16 (53.3%) | |
| Pathological TNM stage | >0.9999 | |||
| 0+I | 26 (48.1%) | 7 (50.0%) | 19 (47.5%) | |
| II+III | 26 (48.2%) | 6 (42.9%) | 20 (50.0%) | |
| IV | 2 (3.7%) | 1 (7.1%) | 1 (2.5%) |
aNot all patients have this information.
NA, not applicable; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma.